MARKET

IMUX

IMUX

Immunic Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.70
+0.71
+4.74%
Opening 10:49 03/08 EST
OPEN
15.00
PREV CLOSE
14.99
HIGH
15.70
LOW
14.62
VOLUME
47.27K
TURNOVER
--
52 WEEK HIGH
28.21
52 WEEK LOW
4.190
MARKET CAP
332.34M
P/E (TTM)
-5.3562
1D
5D
1M
3M
1Y
5Y
Immunic, Inc. to Participate in Industry and Investor Conferences in March
PR Newswire · 6d ago
Wedbush Sticks to Its Buy Rating for Immunic (IMUX)
Wedbush analyst Liana Moussatos reiterated a Buy rating on Immunic (IMUX) yesterday and set a price target of $72.00. The company's shares closed last
SmarterAnalyst · 6d ago
10-K: IMMUNIC, INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. The following discussion and...
Edgar Online - (EDG = 10Q, 10K) · 02/26 12:22
Immunic EPS beats by $0.05
Immunic (IMUX): FY GAAP EPS of -$2.81 beats by $0.05.Cash and Cash Equivalents of $127.5MPress Release
Seekingalpha · 02/26 11:46
Immunic FY Loss/Shr $2.81 >IMUX
Immunic FY Loss/Shr $2.81 >IMUX
Dow Jones · 02/26 11:33
Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity
, /PRNewswire/ -- a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced financial results for the year ended and highlighted...
PR Newswire - PRF · 02/26 11:30
Press Release: Immunic, Inc. Reports Year End -2-
Dow Jones · 02/26 11:30
Wedbush Reaffirms Their Buy Rating on Immunic (IMUX)
Wedbush analyst Liana Moussatos reiterated a Buy rating on Immunic (IMUX) yesterday and set a price target of $72.00. The company's shares closed last
SmarterAnalyst · 02/22 01:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMUX. Analyze the recent business situations of Immunic Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMUX stock price target is 60.83 with a high estimate of 72.00 and a low estimate of 45.00.
EPS
Institutional Holdings
Institutions: 101
Institutional Holdings: 9.89M
% Owned: 46.74%
Shares Outstanding: 21.17M
TypeInstitutionsShares
Increased
28
893.74K
New
21
653.05K
Decreased
16
364.70K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.40%
Pharmaceuticals & Medical Research
+1.10%
Key Executives
President/Chief Executive Officer/Director
Daniel Vitt
Chief Financial Officer/Chief Accounting Officer/Vice President - Finance
Glenn Whaley
Chief Operating Officer
Manfred Groppel
Chief Scientific Officer
Hella Kohlhof
Other
Andreas Muehler
Independent Director
Tamar Howson
Independent Director
Jorg Neermann
Independent Director
Vincent Ossipow
Independent Director
Barclay Phillips
Independent Director
Jan Van den Bossche
No Data
About IMUX
Immunic, Inc., formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.

Webull offers kinds of Immunic Inc stock information, including NASDAQ:IMUX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMUX stock methods without spending real money on the virtual paper trading platform.